Cell Therapy Catapult partners with University of Birmingham, Cancer Research Tech to develop CAR-T cell immuno-oncology therapy

UK based Cell Therapy Catapult on Wednesday said it is has partnered with Cancer Research Technology and the University of Birmingham to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.

The collaborating partners have launched a new company, Chimeric Therapeutics Ltd. The new company will hold all future intellectual property (IP) rights to the resultant discoveries.

Keith Thompson, chief executive at Cell Therapy Catapult, said: “The Cell Therapy Catapult has extensive experience in working with early stage cell and gene therapies to develop them for clinical trial and commercialization. We are delighted to assist Cancer Research Technology and Birmingham University to form this new company, Chimeric Technologies and apply this new CAR-T target to address solid tumors for the benefit of patients. The Cell Therapy Catapult look forward to developing partnerships with other Cancer Research UK supported academic groups.”